Safety and tolerability of docetaxel, cyclophosphamide, and trastuzumab compared to standard trastuzumab-based chemotherapy regimens for early-stage human epidermal growth factor receptor 2-positive breast cancer.

Jitawatanarat, Potjana; O'Connor, Tracey L; Kossoff, Ellen B; Levine, Ellis G; Chittawatanarat, Kaweesak; Ngamphaiboon, Nuttapong

Jitawatanarat, Potjana; O'Connor, Tracey L; Kossoff, Ellen B; Levine, Ellis G; Chittawatanarat, Kaweesak; Ngamphaiboon, Nuttapong.

Afiliação

Jitawatanarat P; Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA.
O'Connor TL; Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA.
Kossoff EB; Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA.
Levine EG; Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA.
Chittawatanarat K; Department of Surgery, Chiang Mai University, Chiang Mai, Thailand.
Ngamphaiboon N; Department of Internal Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

J Breast Cancer ; 17(4): 356-62, 2014 Dec.

Article em En | MEDLINE | ID: mdl-25548584